UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 25, 2008
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Florida
|
|
000-27836
|
|
65-0643773 |
|
|
|
|
|
|
| (State or other
|
|
(Commission
|
|
(IRS Employer |
| jurisdiction of
|
|
File Number)
|
|
Identification No.) |
| incorporation) |
|
|
|
|
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 20100
(Address of principal executive offices) (Zip Code)
(Former Name or Former Address, if Changed Since Last Report)
Registrant’s telephone number, including area code: +972-4-988-9488
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01. Regulation FD Disclosure
On November 25, 2008, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing that Dr. David Aviezer, the Company’s President and Chief Executive Officer, will
present at the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008 at
1:00 PM ET. The conference is being held at the New York Palace Hotel in New York City. A copy of
the press release is furnished as Exhibit 99.1.
An audio webcast of the corporate presentation will be available on the Company’s website at
www.protalix.com under the events calendar section.
The information in Item 7.01 of this report (including Exhibit 99.1) is being furnished pursuant to
Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of
that section, nor shall it be deemed to be incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act.
Item 8.01. Other Events
On December 2, 2008, the Company issued a press release announcing that it has completed enrollment
in the Company’s pivotal phase III clinical trial of prGCD for the treatment of Gaucher disease, a
rare and serious lysosomal storage disorder in humans. A copy of the press release is attached
hereto as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits
| 99.1 |
|
Press release dated November 25, 2008. |
| |
| 99.2 |
|
Press release dated December 2, 2008. |
2